Literature DB >> 21824722

The prophylactic use of an antiepileptic drug in intracerebral hemorrhage.

Robert T Reddig1, Kathryn E Nixdorf, Matthew B Jensen.   

Abstract

OBJECTIVE: Patients with intracerebral hemorrhage (ICH) are at increased risk for both early seizures and later epilepsy. There is a common, but unproven, practice of prescribing a prophylactic antiepileptic drug (PAED) to prevent seizures, but the safety and efficacy of this practice is unclear, as is the optimal drug for this purpose. The objective of the study is to evaluate whether patients presenting with acute, spontaneous intracerebral hemorrhage (ICH) benefit from prescription of prophylactic antiepileptic drug (PAED).
METHOD: All patients with a discharge diagnosis of acute, spontaneous ICH admitted to our institution in the calendar years 2004 and 2007 were included. We retrospectively reviewed the records for baseline characteristics, hospital course, PAED use, early seizures, length of stay, discharge disposition, and death.
RESULTS: 157 patients met our criteria for review. 46 (29%) patients were placed on a PAED. 12 (7.6%) had early seizures. 11% of patients placed on a PAED had an early seizure versus 6.3% who not placed on a PAED. Death or hospice discharge was less common in patients prescribed a PAED, while length of stay was longer, however neither of these differences were significant after adjustment for multiple comparisons. INTERPRETATIONS: Our study confirms previous reports that patients with acute, spontaneous ICH are at an increased risk for early seizures. PAED use in our series was not significantly associated with the risk of early seizures, long-term epilepsy, disability, or death. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824722      PMCID: PMC3215779          DOI: 10.1016/j.clineuro.2011.07.008

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  The ICH score: a simple, reliable grading scale for intracerebral hemorrhage.

Authors:  J C Hemphill; D C Bonovich; L Besmertis; G T Manley; S C Johnston
Journal:  Stroke       Date:  2001-04       Impact factor: 7.914

2.  Seizures after spontaneous supratentorial intracerebral hemorrhage.

Authors:  Stefano Passero; Raffaele Rocchi; Símone Rossi; Monica Ulivelli; Giampaolo Vatti
Journal:  Epilepsia       Date:  2002-10       Impact factor: 5.864

3.  Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome.

Authors:  P M Vespa; K O'Phelan; M Shah; J Mirabelli; S Starkman; C Kidwell; J Saver; M R Nuwer; J G Frazee; D A McArthur; N A Martin
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

4.  Prophylactic antiepileptic drug use is associated with poor outcome following ICH.

Authors:  Steven R Messé; Lauren H Sansing; Brett L Cucchiara; Susan T Herman; Patrick D Lyden; Scott E Kasner
Journal:  Neurocrit Care       Date:  2009-03-25       Impact factor: 3.210

5.  Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry.

Authors:  Simona Sacco; Carmine Marini; Danilo Toni; Luigi Olivieri; Antonio Carolei
Journal:  Stroke       Date:  2008-11-26       Impact factor: 7.914

6.  Anticonvulsant use and outcomes after intracerebral hemorrhage.

Authors:  Andrew M Naidech; Rajeev K Garg; Storm Liebling; Kimberly Levasseur; Micheal P Macken; Stephan U Schuele; H Hunt Batjer
Journal:  Stroke       Date:  2009-09-24       Impact factor: 7.914

  6 in total
  10 in total

1.  Seizures and epilepsy after intracerebral hemorrhage: an update.

Authors:  Laurent Derex; Sylvain Rheims; Laure Peter-Derex
Journal:  J Neurol       Date:  2021-02-10       Impact factor: 4.849

Review 2.  Intracranial hemorrhage.

Authors:  J Alfredo Caceres; Joshua N Goldstein
Journal:  Emerg Med Clin North Am       Date:  2012-08       Impact factor: 2.264

3.  Prophylactic Antiepileptic Drug Use and Outcome in the Ethnic/Racial Variations of Intracerebral Hemorrhage Study.

Authors:  Kevin N Sheth; Sharyl R Martini; Charles J Moomaw; Sebastian Koch; Mitchell S V Elkind; Gene Sung; Steven J Kittner; Michael Frankel; Jonathan Rosand; Carl D Langefeld; Mary E Comeau; Salina P Waddy; Jennifer Osborne; Daniel Woo
Journal:  Stroke       Date:  2015-10-15       Impact factor: 7.914

4.  Confounding by indication in retrospective studies of intracerebral hemorrhage: antiepileptic treatment and mortality.

Authors:  Thomas W K Battey; Guido J Falcone; Alison M Ayres; Kristin Schwab; Anand Viswanathan; Kristen A McNamara; Zora Y DiPucchio; Steven M Greenberg; Kevin N Sheth; Joshua N Goldstein; Jonathan Rosand
Journal:  Neurocrit Care       Date:  2012-12       Impact factor: 3.210

5.  Prophylactic Use of Antiepileptic Drugs in Patients with Spontaneous Intracerebral Hemorrhage.

Authors:  Ali Zandieh; Steven R Messé; Brett Cucchiara; Michael T Mullen; Scott E Kasner
Journal:  J Stroke Cerebrovasc Dis       Date:  2016-06-08       Impact factor: 2.136

6.  Seizures do not increase in-hospital mortality after intracerebral hemorrhage in the nationwide inpatient sample.

Authors:  Michael T Mullen; Scott E Kasner; Steven R Messé
Journal:  Neurocrit Care       Date:  2013-08       Impact factor: 3.210

7.  Continuous Electroencephalography (cEEG) Monitoring and Outcomes of Critically Ill Patients.

Authors:  Ayaz M Khawaja; Guoqiao Wang; Gary R Cutter; Jerzy P Szaflarski
Journal:  Med Sci Monit       Date:  2017-02-04

8.  Prophylactic Anticonvulsants in Patients Undergoing Craniotomy: A Single-Center Experience.

Authors:  Aydemir Kale
Journal:  Med Sci Monit       Date:  2018-04-27

9.  Seizures after spontaneous intracerebral hemorrhage.

Authors:  Kwang-Moo Woo; Seung-Yeob Yang; Keun-Tae Cho
Journal:  J Korean Neurosurg Soc       Date:  2012-10-22

10.  Post-stroke seizure-Do the locations, types and managements of stroke matter?

Authors:  Shrikant D Pande; May Thiri Lwin; Kaung Myat Kyaw; Aye Aye Khine; Aye Aye Thant; May Myat Win; Julie Morris
Journal:  Epilepsia Open       Date:  2018-07-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.